These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 15607733

  • 1. Amiloride potentiates TRAIL-induced tumor cell apoptosis by intracellular acidification-dependent Akt inactivation.
    Cho YL, Lee KS, Lee SJ, Namkoong S, Kim YM, Lee H, Ha KS, Han JA, Kwon YG, Kim YM.
    Biochem Biophys Res Commun; 2005 Jan 28; 326(4):752-8. PubMed ID: 15607733
    [Abstract] [Full Text] [Related]

  • 2. Amiloride augments TRAIL-induced apoptotic death by inhibiting phosphorylation of kinases and phosphatases associated with the P13K-Akt pathway.
    Kim KM, Lee YJ.
    Oncogene; 2005 Jan 13; 24(3):355-66. PubMed ID: 15558024
    [Abstract] [Full Text] [Related]

  • 3. eNOS protects prostate cancer cells from TRAIL-induced apoptosis.
    Tong X, Li H.
    Cancer Lett; 2004 Jul 08; 210(1):63-71. PubMed ID: 15172122
    [Abstract] [Full Text] [Related]

  • 4. Selective Akt inactivation and tumor necrosis actor-related apoptosis-inducing ligand sensitization of renal cancer cells by low concentrations of paclitaxel.
    Asakuma J, Sumitomo M, Asano T, Asano T, Hayakawa M.
    Cancer Res; 2003 Mar 15; 63(6):1365-70. PubMed ID: 12649200
    [Abstract] [Full Text] [Related]

  • 5. Low glucose-enhanced TRAIL cytotoxicity is mediated through the ceramide-Akt-FLIP pathway.
    Nam SY, Amoscato AA, Lee YJ.
    Oncogene; 2002 Jan 17; 21(3):337-46. PubMed ID: 11821946
    [Abstract] [Full Text] [Related]

  • 6. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
    Ravi R, Bedi A.
    Cancer Res; 2002 Aug 01; 62(15):4180-5. PubMed ID: 12154014
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Galectin-3 inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by activating Akt in human bladder carcinoma cells.
    Oka N, Nakahara S, Takenaka Y, Fukumori T, Hogan V, Kanayama HO, Yanagawa T, Raz A.
    Cancer Res; 2005 Sep 01; 65(17):7546-53. PubMed ID: 16140916
    [Abstract] [Full Text] [Related]

  • 10. Sensitization of multidrug resistant human ostesarcoma cells to Apo2 Ligand/TRAIL-induced apoptosis by inhibition of the Akt/PKB kinase.
    Cenni V, Maraldi NM, Ruggeri A, Secchiero P, Del Coco R, De Pol A, Cocco L, Marmiroli S.
    Int J Oncol; 2004 Dec 01; 25(6):1599-608. PubMed ID: 15547696
    [Abstract] [Full Text] [Related]

  • 11. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
    Zhang XD, Wu JJ, Gillespie S, Borrow J, Hersey P.
    Clin Cancer Res; 2006 Feb 15; 12(4):1355-64. PubMed ID: 16489094
    [Abstract] [Full Text] [Related]

  • 12. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells.
    Lashinger LM, Zhu K, Williams SA, Shrader M, Dinney CP, McConkey DJ.
    Cancer Res; 2005 Jun 01; 65(11):4902-8. PubMed ID: 15930312
    [Abstract] [Full Text] [Related]

  • 13. Protein kinase C inhibition and x-linked inhibitor of apoptosis protein degradation contribute to the sensitization effect of luteolin on tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cancer cells.
    Shi RX, Ong CN, Shen HM.
    Cancer Res; 2005 Sep 01; 65(17):7815-23. PubMed ID: 16140950
    [Abstract] [Full Text] [Related]

  • 14. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
    Izeradjene K, Douglas L, Delaney A, Houghton JA.
    Clin Cancer Res; 2004 Oct 01; 10(19):6650-60. PubMed ID: 15475455
    [Abstract] [Full Text] [Related]

  • 15. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
    Ng CP, Zisman A, Bonavida B.
    Prostate; 2002 Dec 01; 53(4):286-99. PubMed ID: 12430140
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways.
    Secchiero P, Gonelli A, Carnevale E, Milani D, Pandolfi A, Zella D, Zauli G.
    Circulation; 2003 May 06; 107(17):2250-6. PubMed ID: 12668516
    [Abstract] [Full Text] [Related]

  • 18. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer.
    Chen X, Thakkar H, Tyan F, Gim S, Robinson H, Lee C, Pandey SK, Nwokorie C, Onwudiwe N, Srivastava RK.
    Oncogene; 2001 Sep 20; 20(42):6073-83. PubMed ID: 11593415
    [Abstract] [Full Text] [Related]

  • 19. Sensitization of mesothelioma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by heat stress via the inhibition of the 3-phosphoinositide-dependent kinase 1/Akt pathway.
    Pespeni MH, Hodnett M, Abayasiriwardana KS, Roux J, Howard M, Broaddus VC, Pittet JF.
    Cancer Res; 2007 Mar 15; 67(6):2865-71. PubMed ID: 17363610
    [Abstract] [Full Text] [Related]

  • 20. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.
    Nimmanapalli R, Perkins CL, Orlando M, O'Bryan E, Nguyen D, Bhalla KN.
    Cancer Res; 2001 Jan 15; 61(2):759-63. PubMed ID: 11212279
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.